BusinessGalectin Therapeutics Granted Patents in China and Japan that Support NASH and Cancer Immunotherapy Clinical Development ProgramsBy Nasdaq OMXJan 25, 2018, 1:31 PM UTC
BusinessImmuron Commences US Non-Deal Institutional Investor RoadshowBy Nasdaq OMXAug 15, 2017, 1:15 PM UTC
BusinessCombination Immunotherapy with Galectin-3 Inhibitor GR-MD-02 Enhances Effects in Pre-clinical Models and Early Results of Phase 1 Clinical TrialsBy Nasdaq OMXFeb 7, 2017, 9:40 PM UTC
